Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Cochrane, Tara; Campbell, Belinda A.; Gangatharan, Shane; Latimer, Maya; Khor, Richard; Christie, David; Gilbertson, Michael; Ratnasingam, Sumita; Palfreyman, Emma; Lee, Hui Peng; Trotman, Judith; Hertzberg, Mark; Dickinson, Michael

doi:10.1111/imj.15503

Cited by 1 publication

(1 citation statement)

References 65 publications

(99 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The schedule of imaging was as per local institution guidelines, however all LaRDR sites use PET‐CT for staging and end of treatment response which were assessed by participating sites according to the Lugano criteria 12 . Surveillance imaging is not a recommended strategy in Australia, 13 hence is not routinely collected as part of the LaRDR. PFS was calculated using Kaplan–Meier analysis with covariates analysed using log rank method.…”

Section: Methodsmentioning

confidence: 99%

Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry

Nguyen

Wellard

Chung

et al. 2022

European J of Haematology

Self Cite

View full text Add to dashboard Cite

Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real‐world data of 498 eligible patients from the first 5 years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype, and treatment patterns in first‐line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most common therapy for both early and advanced‐stage disease, and 48% of patients with the early‐stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients ≥60 years of age with advanced‐stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early‐stage disease, and 88% in advanced‐stage disease. Early progression‐free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies.

show abstract

Section: Methodsmentioning

confidence: 99%